Abstract: A process is disclosed for the preparation of a compound of the formula (XI) ##STR1## or a salt thereof, wherein R.sup.1 is hydrogen, halogen, C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.3 alkoxy, or trifluoromethyl;R.sup.5 is amino or C.sub.1 to C.sub.4 alkoxycarbonylamino; andR.sup.4" is C.sub.1 to C.sub.6 alkyl, C.sub.2 to C.sub.6 alkenyl, C.sub.2 to C.sub.6 alkynyl, cyclohexyl, benzyl, or 2-phenyl-ethyl, which comprises the steps of:(a) reacting a compound of the formula (VIII) ##STR2## or a salt thereof, with a basic nucleophilic compound to yield a salt of the formula (IX) ##STR3## wherein R.sup.4' is a lone pair of electrons, in which case an alkali metal or alkali earth metal cation forms a salt with the sulfur atom; and(b) reacting a salt of the formula (IX) with a compound of the formula (X)R.sup.4' --QwhereinQ is hydroxyl, halogen, 1/2SO.sub.4, 1/3PO.sub.3, SO.sub.3 C.sub.6 H.sub.5, or SO.sub.3 C.sub.6 H.sub.4 CH.sub.3 to yield the desired product.

Abstract: A new process is disclosed for the preparation of a compound of the formula (VIII) ##STR1## wherein R.sup.1 is hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-3 alkoxy, or trifluoromethyl;R.sup.5 is amino or C.sub.1-4 alkoxycarbonylamino; or a salt thereof, which comprises reacting a compound of the formula (II) ##STR2## with gaseous chlorine and a rhodanide of the formula (III)R--SCN (III)wherein R represents a metal ion or ammonium.

Abstract: The invention concerns a new process for the preparation of 5-halo-6,9.alpha.-oxido-prostaglandin derivatives of the general formula II ##STR1## wherein R.sup.1 represents a hydrogen atom, an alkyl group optionally substituted by aryl, amino, hydroxyl or a halogen atom, an equivalent of a pharmaceutically acceptable organic or inorganic cation or a conventional hydroxyl protecting group;R.sup.2 represents a hydrogen atom, a hydroxyl group or a conventionally protected hydroxyl group;R.sup.3 is a hydrogen atom or a lower alkyl group;R.sup.4 represents a hydrogen atom or a conventional hydroxyl protecting group;R.sup.5 stands for a straight or branched chained alkyl group, optionally containing hetero atom(s) and optionally substituted by a substituted or unsubstituted aryl group, andX stands for a halogen atom,which comprises subsjecting prostaglandin F.sub.2.alpha.

Abstract: An anti-inflammatory analgesic pharmaceutical composition comprising as active ingredient a compound of the formula I ##SPC1##whereinR is a phenyl, chlorophenyl, naphthyl, pyrole, furane, furazole, thiazole, thiadiazole or pyridine group;R.sup.1 is hydrogen or alkyl having 1 to 7 carbon atoms;R.sup.2 is hydrogen, alkyl having 1 to 7 carbon atoms, alkoxy having 1 to 7 carbon atoms or dialkylamino having 1 to 7 carbon atoms per alkyl group in admixture with a pharmaceutical carrier.